GSK (NYSE:GSK) Downgraded to Buy Rating by StockNews.com

GSK (NYSE:GSK) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Sunday.

Other equities analysts have also recently issued research reports about the stock. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, GSK currently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Trading Down 1.4 %

NYSE GSK opened at $33.47 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $69.37 billion, a price-to-earnings ratio of 21.73, a PEG ratio of 1.52 and a beta of 0.63. The stock’s 50-day simple moving average is $34.75 and its two-hundred day simple moving average is $38.43. GSK has a twelve month low of $32.83 and a twelve month high of $45.92.

Hedge Funds Weigh In On GSK

Several hedge funds have recently made changes to their positions in GSK. FMR LLC increased its position in GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Fisher Asset Management LLC boosted its stake in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Primecap Management Co. CA increased its position in shares of GSK by 2.4% during the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after buying an additional 342,365 shares during the period. Provident Trust Co. grew its holdings in shares of GSK by 1.7% during the 3rd quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock worth $161,623,000 after acquiring an additional 66,765 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC raised its holdings in GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after purchasing an additional 833,080 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.